Jeremy Laurance: Why spare the drug companies?

We cannot provide every treatment to every patient regardless of cost

Share

Why are Britain's health charities bent on sucking the blood from the NHS? The very same organisations that do such sterling work funding research, supporting patients and promoting awareness appear to have a blind spot when it comes to assessing what treatments are worth. We see it each time the National Institute for Health and Clinical Excellence (Nice) reaches an unpopular decision to ban a drug on the NHS because it is too expensive, as it did yesterday with the new prostate cancer medicine abiraterone. Cue uproar from charities.

"This decision is a bitter blow to thousands of men and their families and must be overturned," said Owen Sharp, the chief executive of the Prostate Cancer Charity. It was the same last month, when Nice ruled against three bowel cancer drugs. Mark Flannagan, the chief excecutive of Beating Bowel Cancer, said: "This is yet another blow for bowel cancer patients. All bowel cancer patients deserve the best care." Of course – how could anyone dispute that? Nice agreed that some of the drugs were effective – extending life by an average of 3.9 months in the case of prostate cancer. As Mr Sharp said, that could give a terminally ill man the chance to "walk his daughter down the aisle or see the birth of a grandchild". It is a disaster for such a man to be denied such a drug.

But we cannot provide every treatment that is effective to every patient who would benefit without regard to the cost. If we did, we would quickly bankrupt the NHS. Yet that is what the health charities are helping to do. By turning their fire on Nice, and neglecting the other player in the tragedy – the drug company involved – charities are effectively saying that protecting drug-company profits is more important than protecting the NHS.

Nice assesses each drug and calculates how much benefit it delivers for the cost. It mostly approves drugs costing up to £30,000 per Quality Adjusted Life Year (Qaly – a measure of the benefit), or for terminal conditions, up to £50,000. In this case, the prostate drug came in at £63,000 per Qaly, and the bowel cancer drugs at £110,000 per Qaly. So, in Nice's view, the drug companies Janssen and Amgen were charging more than they were worth. Did the health charities challenge the companies? No. Instead, they lambasted Nice. Do they receive drug company financial support? Perhaps we should be told.

Only Harpal Kumar, the chief executive of Cancer Research UK, struck the right note. Commenting on the prostate drug decision yesterday, he said: "We feel extremely let down that the drug's manufacturer couldn't offer Nice a price they could agree on." This is a £500bn global industry and it is time other organistations joined Nice in holding it to account to ensure fair prices are charged to the NHS.

j.laurance@independent.co.uk

React Now

Latest stories from i100
Have you tried new the Independent Digital Edition apps?
iJobs Job Widget
iJobs General

SQL Implementation Consultant (VB,C#, SQL, Java, Eclipse, integ

£40000 - £50000 per annum + benefits+bonus+package: Harrington Starr: SQL Impl...

SQL Technical Implementation Consultant (Java, BA, Oracle, VBA)

£45000 - £55000 per annum + Benefits + Bonus: Harrington Starr: SQL Technical ...

Head of IT (Windows, Server, VMware, SAN, Fidessa, Equities)

£85000 per annum: Harrington Starr: Head of IT (Windows, Server, VMware, SAN, ...

Lead C# Developer (.Net, nHibernate, MVC, SQL) Surrey

£55000 - £60000 per annum + Benefits + Bonus: Harrington Starr: Lead C# Develo...

Day In a Page

 

i Editor's Letter: Still all to play for at our live iDebate

Oliver Duff Oliver Duff
'I’ll tell you what I would not serve - lamb and potatoes': US ambassador hits out at stodgy British food served at diplomatic dinners

'I’ll tell you what I would not serve - lamb and potatoes'

US ambassador hits out at stodgy British food
Radio Times female powerlist: A 'revolution' in TV gender roles

A 'revolution' in TV gender roles

Inside the Radio Times female powerlist
Endgame: James Frey's literary treasure hunt

James Frey's literary treasure hunt

Riddling trilogy could net you $3m
Fitbit: Because the tingle feels so good

Fitbit: Because the tingle feels so good

What David Sedaris learnt about the world from his fitness tracker
Saudis risk new Muslim division with proposal to move Mohamed’s tomb

Saudis risk new Muslim division with proposal to move Mohamed’s tomb

Second-holiest site in Islam attracts millions of pilgrims each year
Alexander Fury: The designer names to look for at fashion week this season

The big names to look for this fashion week

This week, designers begin to show their spring 2015 collections in New York
Will Self: 'I like Orwell's writing as much as the next talented mediocrity'

'I like Orwell's writing as much as the next talented mediocrity'

Will Self takes aim at Orwell's rules for writing plain English
Meet Afghanistan's middle-class paint-ballers

Meet Afghanistan's middle-class paint-ballers

Toy guns proving a popular diversion in a country flooded with the real thing
Al Pacino wows Venice

Al Pacino wows Venice

Ham among the brilliance as actor premieres two films at festival
Neil Lawson Baker interview: ‘I’ve gained so much from art. It’s only right to give something back’.

Neil Lawson Baker interview

‘I’ve gained so much from art. It’s only right to give something back’.
The other Mugabe who is lining up for the Zimbabwean presidency

The other Mugabe who is lining up for the Zimbabwean presidency

Wife of President Robert Mugabe appears to have her sights set on succeeding her husband
The model of a gadget launch: Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed

The model for a gadget launch

Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed
Alice Roberts: She's done pretty well, for a boffin without a beard

She's done pretty well, for a boffin without a beard

Alice Roberts talks about her new book on evolution - and why her early TV work drew flak from (mostly male) colleagues
Get well soon, Joan Rivers - an inspiration, whether she likes it or not

Get well soon, Joan Rivers

She is awful. But she's also wonderful, not in spite of but because of the fact she's forever saying appalling things, argues Ellen E Jones
Doctor Who Into the Dalek review: A classic sci-fi adventure with all the spectacle of a blockbuster

A fresh take on an old foe

Doctor Who Into the Dalek more than compensated for last week's nonsensical offering